Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Dyno Therapeutics.

    Client Virtual Booth

    DYNO THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Dyno Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    LabCentral 610 Main St. Cambridge, MA 02139
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.dynotx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/dynotx/
    Twitter
    Twitter
    https://twitter.com/dyno_tx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle

    Details:

    Under the terms of agreement, Dyno will design novel AAV capsids with improved functional properties for gene therapy, while Astellas will be responsible for conducting preclinical, clinical and commercialization activities, of gene therapy candidates using the novel capsids.


    Lead Product(s): AAV Capsids

    Therapeutic Area: Genetic Disease Product Name: Undisclosed

    Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Astellas Pharma

    Deal Size: $1,618.0 million Upfront Cash: $18.0 million

    Deal Type: Collaboration December 02, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Dyno Therapeutics Closes $100 Million Series A Financing Led by Andreessen Horowitz to Accelerate AI-Powered Gene Therapy Platform

    Details:

    Funds from this financing will directly fund expansion of the company’s CapsidMap™ platform, which uses AI technology for the design of novel Adeno-Associated Virus (AAV) gene therapy vectors.


    Lead Product(s): AAV based-gene therapy

    Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

    Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Andreessen Horowitz

    Deal Size: $100.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing May 06, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Dyno Therapeutics Join Hands With Roche to Develop Next-Generation AAV Gene Therapy Vectors for CNS Diseases and Liver-Directed Therapies

    Details:

    Dyno will design novel AAV capsids with improved functional properties for gene therapy, while Roche and Spark Therapeutics will be conducting preclinical, clinical and commercialization activities for gene therapy product candidates using the novel capsids.


    Lead Product(s): AAV vectors based gene therapies

    Therapeutic Area: Neurology Product Name: Undisclosed

    Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

    Deal Size: $1,800.0 million Upfront Cash: Undisclosed

    Deal Type: Collaboration October 14, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Dyno Therapeutics Announces Presentations at 2020 American Society of Gene and Cell Therapy Conference

    Details:

    The presentation will highlight results from Dyno's study on Artificial intelligence powered design of synthetic AAV capsids without pre-existing immunity for the universal treatment of all patients.


    Lead Product(s): Synthetic AAV capsids Proteins

    Therapeutic Area: Immunology Product Name: Undisclosed

    Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 12, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search